chitosan / LDH Cancer Research Results

Chit, chitosan: Click to Expand ⟱
Features:

Chitosan — Chitosan is a deacetylated chitin-derived cationic polysaccharide used as a biocompatible biomaterial, immune-active adjuvant, and multifunctional delivery polymer rather than a standard standalone cytotoxic anticancer drug. Its formal classification is a natural polymeric biomaterial and drug-delivery excipient/platform. Standard abbreviations include CS; related derivatives include chitooligosaccharides and glycated chitosan in some oncology contexts. It is typically sourced from crustacean shells, though fungal sources also exist. In cancer research, its importance is driven mainly by mucoadhesion, protonatable amines, cargo complexation, endosomal interaction, and formulation-tunable immune and tumor-microenvironment effects; biological behavior depends strongly on molecular weight, degree of deacetylation, pattern of substitution, and formulation architecture. Low–molecular weight chitosan and modified forms have also been reported to inhibit angiogenesis, modulate tumor microenvironment acidity, interfere with metastasis, and induce apoptosis in some in vitro systems. A major translational role of chitosan is as a nanoparticle carrier for chemotherapeutics, genes, and immunotherapies, improving stability and targeted delivery. Effects vary significantly depending on molecular weight, degree of deacetylation, and formulation.

Primary mechanisms (ranked):

Chitosan has been shown to inhibit the growth of various types of cancer cells, including breast, lung, and colon cancer cells.
Chitosan has been shown to inhibit angiogenesis, stimulate the immune system, and anti-inflammatory.

Chitosan is only soluble in acidic settings, hence limiting its use in neutral or alkaline pH circumstances
  1. Drug and gene delivery enhancement via cationic complexation, mucoadhesion, cellular uptake facilitation, and controlled/stimuli-responsive release
  2. Innate immune activation and adjuvanticity, including dendritic-cell and macrophage engagement with downstream NK-cell support
  3. Tumor microenvironment and cytokine modulation, which can favor antitumor immune tone in selected formulations
  4. Direct antiproliferative and pro-apoptotic signaling in cancer cells, usually derivative-, molecular-weight-, and formulation-dependent rather than a robust native-CS class effect
  5. Anti-migratory and anti-invasive effects, including reported suppression of MMP-linked metastatic behavior in some models
  6. Anti-angiogenic effects in selected low-molecular-weight or modified systems
  7. Secondary redox modulation, usually downstream of formulation or cell-stress effects rather than a core redox pharmacology

Bioavailability / PK relevance: Chitosan is not a conventional systemically bioavailable small molecule. Native CS has limited neutral-pH solubility and its translational behavior is dominated by route, particle size, surface chemistry, molecular weight, and degree of deacetylation. Oncology relevance is strongest in local, mucosal, intratumoral, hydrogel, nanoparticle, and carrier-based applications rather than free systemic exposure.

In-vitro vs systemic exposure relevance: Many direct in-vitro anticancer studies use concentrations, contact conditions, or modified chitosan constructs that are not straightforwardly comparable to achievable systemic exposure of native CS. Therefore, carrier/platform effects and local-delivery applications are more clinically plausible than relying on native chitosan as a systemic concentration-driven anticancer agent.

Clinical evidence status: Predominantly preclinical for direct anticancer use. Human oncology evidence is limited and mostly adjunctive, formulation-specific, or device/supportive-care related. There is no established regulatory status for chitosan as a standalone approved anticancer drug, although chitosan-containing or chitosan-derived oncology platforms and local immunotherapy approaches have entered early clinical investigation.

Mechanistic pathway table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Drug and gene delivery platform Drug uptake ↑; nucleic-acid delivery ↑; tumor retention ↑ (formulation-dependent) Off-target exposure ↓ (potential); mucosal penetration ↑ P, R, G Therapeutic leverage platform Most clinically relevant oncology role. Cationic amino groups enable cargo binding, surface functionalization, and controlled release; many benefits are formulation-driven rather than intrinsic cytotoxicity.
2 Innate immune activation and adjuvanticity Immune-mediated tumor pressure ↑; DC activation ↑; NK support ↑ Innate immune responsiveness ↑ R, G Immunostimulatory Chitosan and some derivatives act as immune adjuvants and can enhance antigen presentation and antitumor immune priming.
3 Cytokine and tumor microenvironment modulation Pro-tumor immune suppression ↓ (context-dependent); IL-12 / IFN-γ / TNF-α tone ↑ (reported) Immune tone ↔ or ↑ R, G Microenvironment remodeling Relevant mainly in immune-active formulations such as nanoparticles, vaccine adjuvants, and glycated chitosan-based local immunotherapy systems.
4 Apoptosis and mitochondrial stress Apoptosis ↑; MMP ↓; caspase signaling ↑ (derivative-dependent) Usually milder injury at comparable exposures G Context-dependent direct anticancer effect Direct tumor-cell killing is reported, but is much less uniform than delivery/immunology effects and depends strongly on molecular weight, substitution, and nanoformulation.
5 Migration invasion and metastasis axis MMP2 ↓; MMP9 ↓; migration ↓; invasion ↓ ↔ G Anti-metastatic Often observed in modified chitosans or drug-loaded systems; likely linked to altered adhesion, matrix interaction, and signaling restraint.
6 Angiogenesis signaling VEGF axis ↓ (context-dependent); neovascular support ↓ ↔ G Anti-angiogenic Reported mainly for low-molecular-weight or chemically modified chitosan systems and for payload-enabled constructs.
7 Mitochondrial ROS increase (secondary) ROS ↑ or ↔ (model-dependent); oxidative stress ↑ (high concentration only) ROS ↓ or ↔ in some protective contexts R, G Secondary stress modulation Redox behavior is inconsistent across systems and should not be treated as a primary class-defining mechanism for native chitosan.
8 Clinical Translation Constraint Standalone systemic anticancer efficacy uncertain; heterogeneity ↑ Biocompatibility generally favorable, but local irritation / allergy concerns remain — Translation constraint Key limitations are poor neutral-pH solubility of native CS, batch heterogeneity, scale-up and characterization issues, route dependence, and the gap between promising preclinical carrier systems and sparse oncology trial validation.
TSF: P = 0–30 min (surface interactions), R = 30 min–3 hr (immune signaling shifts), G = >3 hr (phenotype and immune outcomes).



LDH, Lactate Dehydrogenase: Click to Expand ⟱
Source:
Type:
LDH is a general term that refers to the enzyme that catalyzes the interconversion of lactate and pyruvate. LDH is a tetrameric enzyme, meaning it is composed of four subunits.
LDH refers to the enzyme as a whole, while LDHA specifically refers to the M subunit. Elevated LDHA levels are often associated with poor prognosis and aggressive tumor behavior, similar to elevated LDH levels.
leakage of LDH is a well-known indicator of cell membrane integrity and cell viability [35]. LDH leakage results from the breakdown of the plasma membrane and alterations in membrane permeability, and is widely used as a cytotoxicity endpoint.

However, it's worth noting that some studies have shown that LDHA is a more specific and sensitive biomarker for cancer than total LDH, as it is more closely associated with the Warburg effect and cancer metabolism.

Dysregulated LDH activity contributes significantly to cancer development, promoting the Warburg effect (Chen et al., 2007), which involves increased glucose uptake and lactate production, even in the presence of oxygen, to meet the energy demands of rapidly proliferating cancer cells (Warburg and Minami, 1923; Dai et al., 2016b). LDHA overexpression favors pyruvate to lactate conversion, leading to tumor microenvironment acidification and aiding cancer progression and metastasis.

Inhibitors:
Flavonoids, a group of polyphenols abundant in fruit, vegetables, and medicinal plants, function as LDH inhibitors.
LDH is used as a clinical biomarker for Synthetic liver function, nutrition

Tier A — Direct LDH Enzyme Inhibitors (Validated Catalytic Inhibition)

Rank Compound Type LDH Target Potency Level Primary Effect Notes
1 NCI-006 Research drug LDHA / LDHB High (in vivo active) Potent glycolysis suppression Modern benchmark LDH inhibitor used in metabolic oncology models.
2 (R)-GNE-140 Research drug LDHA (±LDHB) High (nM range reported) Lactate production ↓ Widely used experimental LDH inhibitor.
3 FX11 Research drug LDHA High (μM range) Metabolic crisis in LDHA-dependent tumors Classic LDHA inhibitor; often increases ROS secondary to metabolic stress.
4 Oxamate Tool compound LDH (pyruvate-competitive) Moderate (mM cellular use) Reduces lactate flux Classical LDH inhibitor; requires high concentrations in cells.
5 Gossypol Natural product derivative LDHA Moderate–High Glycolysis inhibition Also has other targets; safety considerations apply.
6 Galloflavin Natural compound LDH isoforms Moderate Lactate production ↓ One of the better-supported “natural-like” LDH inhibitors.

Tier B — Indirect LDH-Axis Modulators (Glycolysis / Lactate Reduction Without Confirmed Direct Catalytic Inhibition)

Rank Compound Mechanism Type LDH Claim Type Primary Axis Notes / Caution
1 Lonidamine MCT/MPC modulation Lactate axis inhibition Metabolic transport blockade Better classified as lactate/pyruvate transport modulator.
2 Stiripentol Repurposed drug LDH pathway modulation Metabolic axis modulation Emerging oncology interest; primarily neurological drug.
3 Quercetin Flavonoid Reported LDH inhibition (mixed evidence) NF-κB / PI3K modulation Often LDH-release confusion; direct enzymatic proof limited.
4 Ursolic acid Triterpenoid Reported LDH interaction Warburg modulation More credible as metabolic signaling modulator.
5 Fisetin Flavonoid Docking / indirect reports Apoptosis / survival signaling Enzyme inhibition not well validated.
6 Resveratrol Polyphenol Indirect glycolysis suppression AMPK / HIF-1α modulation Reduces lactate via upstream signaling.
7 Curcumin Polyphenol Indirect LDH expression modulation Inflammation + metabolic signaling Bioavailability limits translational strength.
8 Berberine Alkaloid Indirect metabolic modulation AMPK activation Closer to metformin-like metabolic pressure.
9 Honokiol Lignan Indirect glycolysis effects Survival pathway suppression Not validated as catalytic LDH inhibitor.
10 Silibinin Flavonolignan Mixed / indirect reports Inflammation + metabolic axis Often misclassified as LDH inhibitor.
11 Kaempferol Flavonoid Often LDH-release marker confusion Glucose transport / signaling Do not list as direct LDH inhibitor without enzyme data.
12 Oleanolic acid / Limonin / Allicin / Taurine Natural compounds Weak / indirect evidence General metabolic modulation Should not be categorized as true LDH inhibitors.

Tier A = Direct catalytic LDH inhibition (enzyme-level validation).
Tier B = Indirect lactate reduction or glycolytic modulation without strong catalytic inhibition evidence.
Important: LDH release assays (cell damage marker) are not proof of LDH enzymatic inhibition.



Scientific Papers found: Click to Expand⟱
4488- Se,  Chit,  PEG,    Anticancer effect of selenium/chitosan/polyethylene glycol/allyl isothiocyanate nanocomposites against diethylnitrosamine-induced liver cancer in rats
- in-vivo, Liver, HepG2 - in-vivo, Nor, HL7702
tumCV↓, Apoptosis↑, *GSH↑, *VitC↑, *VitE↑, *SOD↑, *GPx↑, *GR↑, ALAT↓, ALP↓, AST↓, LDH↓, selectivity↑, eff↑,
4480- SeNPs,  Chit,    Biogenic synthesized selenium nanoparticles combined chitosan nanoparticles controlled lung cancer growth via ROS generation and mitochondrial damage pathway
- in-vitro, Lung, A549 - in-vitro, Nor, HK-2
selectivity↑, *toxicity↓, ROS↑, mtDam↑, Apoptosis↑, LDH↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

mtDam↑, 1,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,   LDH↓, 1,   LDH↑, 1,  

Cell Death ⓘ

Apoptosis↑, 2,  

Transcription & Epigenetics ⓘ

tumCV↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 1,   selectivity↑, 2,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   ALP↓, 1,   AST↓, 1,   LDH↓, 1,   LDH↑, 1,  
Total Targets: 14

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

GPx↑, 1,   GSH↑, 1,   SOD↑, 1,   VitC↑, 1,   VitE↑, 1,  

Hormonal & Nuclear Receptors ⓘ

GR↑, 1,  

Functional Outcomes ⓘ

toxicity↓, 1,  
Total Targets: 7

Scientific Paper Hit Count for: LDH, Lactate Dehydrogenase
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:210  Target#:906  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page